Related Experiment Video
Updated: Jul 4, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Should Stereotactic Ablative Radiotherapy Be Used for Oligometastatic Disease?
Robert A Olson1, David A Palma2
1The University of British Columbia, Vancouver, BC, Canada.
Abstract:
Should SABR Be Used for Oligometastatic Disease?The efficacy of stereotactic ablative radiotherapy in the oligometastatic setting has not been shown in phase 3 randomized controlled trials for breast (or many other) cancers. We review the evidence base and propose a trial to address the question, should stereotactic ablative radiotherapy be used for oligometastatic disease?
Insights
Stereotactic ablative radiotherapy (SABR) efficacy for oligometastatic cancer is unproven in major trials. Further research, including a proposed trial, is needed to determine if SABR is suitable for oligometastatic disease.
Area of Science:
- Oncology
- Radiation Oncology
Background:
- The role of stereotactic ablative radiotherapy (SABR) in treating oligometastatic disease remains uncertain.
- High-quality evidence from phase 3 randomized controlled trials is lacking for many cancer types, including breast cancer.
Approach:
- This review examines the existing evidence base regarding SABR for oligometastatic cancer.
- A proposal for a new clinical trial is presented to directly address the clinical question.
Key Points:
- Current evidence does not definitively establish the efficacy of SABR in the oligometastatic setting.
- The need for robust clinical trials is highlighted to guide treatment decisions.
Conclusions:
- Further investigation is crucial to determine the appropriate use of SABR for patients with oligometastatic disease.
- The proposed trial aims to provide definitive data on SABR's benefit in this patient population.
